Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
2202 / 7 – The combination of a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, and the angiogenesis inhibitor lucitanib enhances antitumor activity
Advertisement